



Tatva Chintan Pharma Chem Limited

(CIN:L24232GJ1996PLC029894)



Date: 29 August 2023

Ref. No.: TCPCL/SEC/2023-24/00057

To,
The General Manager,
Corporate relationship department,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai-400 001
Scrip Code: 543321

The Manager,
Listing department,
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block-G,
Bandra-Kurla, Complex Bandra(E),
Mumbai-400 051
Scrip Symbol: TATVA

Sub: Qualified institutions placement of equity shares of face value of ₹ 10 each (the “Equity Shares”) by Tatva Chintan Pharma Chem Limited (the “Company”) under the provisions of Chapter VI of Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended (the “SEBI ICDR Regulations”), and Sections 42 and 62 of the Companies Act, 2013 (including the rules made thereunder), as amended (the “Issue”).

Dear Sir/Madam,

Please refer to our letter dated 24 August 2023 intimating you about the meeting of the Fund Raising Committee to be held on or after 29 August 2023 in respect of the Issue.

The Issue was opened on 24 August 2023, and the same was intimated to you vide our letter dated 24 August 2023. We wish to inform you that the Fund Raising Committee at its meeting held today i.e. 29 August 2023 has, *inter alia*, passed the following resolutions:

- Approved the closure of the Issue today (i.e. 29 August 2023) pursuant to the receipt of application forms and the funds in the escrow account from the eligible qualified institutional buyers in accordance with the terms of the Issue; and
- Determined and approved the allocation of 12,26,993 Equity Shares at an Issue price of ₹ 1,630 per Equity Share, which is at a discount of ₹ 74.74 per Equity Share i.e. 4.38% to the floor price of ₹ 1,704.74 per Equity Share, in accordance with the SEBI ICDR Regulations (including a premium of ₹ 1,620 per Equity Share) upon the closure of the Issue, determined according to the formula prescribed under Regulation 176 of the SEBI ICDR Regulations, for the Equity Shares to be allotted to the eligible qualified institutional buyers in the Issue; and
- Approved and finalised the confirmation of allocation note to be sent to eligible qualified institutional buyers, intimating them of the allocation of Equity Shares pursuant to the Issue; and
- Approved and adopted placement document dated 29 August 2023.

The meeting of the Committee commenced at 09:45 p.m. (IST) and concluded at 10:00 p.m. (IST).

We request you to kindly take this on records, and the same be treated as compliance under the applicable regulations of the Securities and Exchange Board of India (Listing Obligations Disclosure Requirements) Regulations, 2015, as amended.

Thanking you,

Yours faithfully,
For Tatva Chintan Pharma Chem Limited

Ishwar Nayi
Company Secretary and Compliance Officer
M. No.: A37444